Literature DB >> 9931432

Effects of apolipoprotein B-100 on the metabolism of a lipid microemulsion model in rats.

R D Hirata1, M H Hirata, C H Mesquita, T B Cesar, R C Maranhão.   

Abstract

In previous studies, it was shown that lipid microemulsions resembling LDL (LDE) but not containing protein, acquire apolipoprotein E when injected into the bloodstream and bind to LDL receptors (LDLR) using this protein as ligand. Aiming to evaluate the effects of apolipoprotein (apo) B-100 on the catabolism of these microemulsions, LDE with incorporated apo B-100 (LDE-apoB) and native LDL, all labeled with radioactive lipids were studied after intraarterial injection into Wistar rats. Plasma decay curves of the labels were determined in samples collected over 10 h and tissue uptake was assayed from organs excised from the animals sacrificed 24 h after injection. LDE-apo B had a fractional clearance rate (FCR) similar to native LDL (0.40 and 0.33, respectively) but both had FCR pronouncedly smaller than LDE (0.56, P<0.01). Liver was the main uptake site for LDE, LDE-apoB, and native LDL, but LDE-apoB and native LDL had lower hepatic uptake rates than LDE. Pre-treatment of the rats with 17alpha-ethinylestradiol, known to upregulate LDLR, accelerated the removal from plasma of both LDE and LDE-apoB, but the effect was greater upon LDE than LDE-apoB. These differences in metabolic behavior documented in vivo can be interpreted by the lower affinity of LDLR for apo B-100 than for apo E, demonstrated in in vitro studies. Therefore, our study shows in vivo that, in comparison with apo E, apo B is a less efficient ligand to remove lipid particles such as microemulsions or lipoproteins from the intravascular compartment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9931432     DOI: 10.1016/s1388-1981(98)00004-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

Review 1.  Learning from biology: synthetic lipoproteins for drug delivery.

Authors:  Huang Huang; William Cruz; Juan Chen; Gang Zheng
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-10-24

2.  Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion.

Authors:  Iara F Kretzer; Durvanei A Maria; Raul C Maranhão
Journal:  Cell Oncol (Dordr)       Date:  2012-10-03       Impact factor: 6.730

3.  Tissue Uptake Mechanisms Involved in the Clearance of Non-Protein Nanoparticles that Mimic LDL Composition: A Study with Knockout and Transgenic Mice.

Authors:  Elaine N Daminelli; Panagiotis Fotakis; Carlos H Mesquita; Raul C Maranhão; Vassilis I Zannis
Journal:  Lipids       Date:  2017-11-01       Impact factor: 1.880

4.  Plasma kinetics of free and esterified cholesterol in familial hypercholesterolemia: effects of simvastatin.

Authors:  Raul D Santos; Ana P M Chacra; Aleksandra Morikawa; Carmen C Vinagre; Raul C Maranhão
Journal:  Lipids       Date:  2005-07       Impact factor: 1.880

5.  Plasma kinetics of a cholesterol-rich emulsion in young, middle-aged, and elderly subjects.

Authors:  L B Pinto; M Wajngarten; E L Silva; C C Vinagre; R C Maranhão
Journal:  Lipids       Date:  2001-12       Impact factor: 1.880

6.  Modification of composition of a nanoemulsion with different cholesteryl ester molecular species: effects on stability, peroxidation, and cell uptake.

Authors:  Cristina P Almeida; Carolina G Vital; Thais C Contente; Durvanei A Maria; Raul C Maranhão
Journal:  Int J Nanomedicine       Date:  2010-09-20

7.  Deposition of free cholesterol in the blood vessels of patients with coronary artery disease: a possible novel mechanism for atherogenesis.

Authors:  Ricardo D Couto; Luís A O Dallan; Luiz A F Lisboa; Carlos H Mesquita; Carmen G C Vinagre; Raul C Maranhão
Journal:  Lipids       Date:  2007-04-19       Impact factor: 1.880

8.  Plasma kinetics of an LDL-like nanoemulsion and lipid transfer to HDL in subjects with glucose intolerance.

Authors:  Marina P Bertato; Carolina P Oliveira; Bernardo L Wajchenberg; Antonio C Lerario; Raul C Maranhão
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

9.  Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: Lack of toxicity and therapeutic benefits.

Authors:  Carolina G Vital; Raul C Maranhão; Fatima R Freitas; Brigitte M Van Eyll; Silvia R Graziani
Journal:  J Bone Oncol       Date:  2022-04-20       Impact factor: 4.491

10.  Lipoprotein metabolism in patients with type 1 diabetes under intensive insulin treatment.

Authors:  Alina C R Feitosa; Gilson S Feitosa-Filho; Fatima R Freitas; Bernardo L Wajchenberg; Raul C Maranhão
Journal:  Lipids Health Dis       Date:  2013-02-11       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.